WHAT IS CLAIMED IS:

1. An agent that binds to and reverses a reduction in blood pressure associated with the administration of a natriuretic peptide receptor 1 (NPR1) agonist, wherein the agent is an immunoglobulin protein.

2. The agent of claim 1, wherein the NPR1 agonist is an antibody or antigen-binding fragment thereof that binds specifically to NPR1.

3. The agent of claim 2, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) comprising SEQ ID NO: 48; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising SEQ ID NO: 52.

4. The agent of claim 2, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) comprising SEQ ID NOs: 49, 50, and 51, respectively; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprising SEQ ID NO: 53, 54, and 55, respectively.

5. The agent of claim 4, wherein the antibody or antigen-binding fragment thereof comprises a HCVR of SEQ ID NO: 48 and a LCVR of SEQ ID NO: 52.

6. The agent of claim 2, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody.

7. The agent of claim 6, wherein the antibody is an IgG1 antibody.

8. The agent of claim 6, wherein the antibody is an IgG4 antibody.

9. The agent of claim 6, wherein the antibody comprises a heavy chain comprising SEQ ID NO: 56 and a light chain comprising SEQ ID NO: 57.

10. The agent of claim 1, wherein the NPR1 agonist is R5381.

11. The agent of claim 1, wherein the immunoglobulin protein comprises at least one immunoglobulin variable domain comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) , wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

12. The agent of claim 11, wherein the immunoglobulin protein comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) comprising amino acid sequences selected from SEQ ID NOs: 4, 6, 8, 12, 14 and 16; or SEQ ID NOs: 24, 26, 28, 32, 34, and 36.

13. The agent of claim 12, wherein the HCVR comprises an amino acid sequence having at least 90%, optionally 95%, 98%, or 99% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2 and 22.

14. The agent of claim 12, wherein the LCVR comprises an amino acid sequence having at least 90%, optionally 95%, 98%, or 99% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

15. The agent of claim 12, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

16. The agent of claim 12, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 2 and the LCVR comprises an amino acid sequence of SEQ ID NO: 10.

17. The agent of claim 12, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 22 and the LCVR comprises an amino acid sequence of SEQ ID NO: 30.

18. The agent of claim 11, wherein the immunoglobulin protein comprises one immunoglobulin variable domain.

19. The agent of claim 18, wherein HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 comprise amino acid sequences selected from the group consisting of (i) SEQ ID NOs: 4, 6, 8, 12, 14 and 16; and (ii) SEQ ID NOs: 24, 26, 28, 32, 34, and 36.

20. The agent of claim 19, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 22; and the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 30.

21. The agent of claim 19, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 2 and the LCVR comprises an amino acid sequence of SEQ ID NO: 10.

22. The agent of claim 19, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 22 and the LCVR comprises an amino acid sequence of SEQ ID NO: 30.

23. The agent of claim 20, wherein the one immunoglobulin variable domain is comprised within a Fab fragment.

24. The agent of claim 23, further comprising a multimerizing component.

25. The agent of claim 24, wherein the multimerizing component comprises at least one Fc fragment.

26. The agent of claim 25, wherein the at least one Fc fragment is of isotype IgG1, IgG4, or a variant thereof.

27. The agent of claim 26, wherein the at least one Fc fragment is of IgG4 isotype.

28. The agent of claim 26, wherein the at least one Fc fragment is of IgG1 isotype.

29. The agent of claim 25, comprising a first Fc fragment and a second Fc fragment, wherein the first Fc fragment or the second Fc fragment, but not both Fc fragments, comprises a modification in the CH3 domain that reduces binding of the immunoglobulin protein to Protein A as compared to an immunoglobulin protein lacking the modification.

30. The agent of claim 29, wherein the modification comprises a H315R substitution and a Y316F substitution (EU numbering) in a Fc fragment.

31. The agent of claim 25, wherein the multimerizing component comprises a first Fc fragment comprising the amino acid sequence of SEQ ID NO: 46 and a second Fc fragment comprising the amino acid sequence of SEQ ID NO: 58.

32. The agent of claim 18, wherein the immunoglobulin variable domain is comprised in a monovalent monoclonal antibody.

33. The agent of claim 32, wherein the monovalent monoclonal antibody comprises a heavy chain comprising a heavy chain constant region and HCVR, and a light chain comprising a LCVR, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 42 and 44; and the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20 and 40.

34. The agent of claim 33, wherein the heavy chain constant region comprises a modification in the CH3 domain that reduces binding of the immunoglobulin protein to Protein A as compared to an immunoglobulin protein lacking the modification.

35. The agent of claim 34, wherein the modification comprises a H315R substitution and a Y316F substitution (EU numbering) in the heavy chain constant region of IgG1 or IgG4 isotype.

36. The agent of claim 33, wherein the immunoglobulin protein further comprises a Fc fragment.

37. The agent of claim 36, wherein the Fc fragment is of IgG1 or IgG4 isotype.

38. The agent of claim 36, wherein the Fc fragment comprises an amino acid sequence of SEQ ID NO: 46.

39. The agent of claim 1, wherein the agent is REGN9035 or REGN9037.

40. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a heavy chain variable region (HCVR) of an immunoglobulin protein as set forth in claim 38.

41. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a light chain variable region (LCVR) of an immunoglobulin protein as set forth in claim 38.

42. A vector comprising the polynucleotide molecule of claim 40 or the polynucleotide molecule of claim 41.

43. A host cell expressing the vector of claim 42.

44. A host cell expressing the polynucleotide molecule of claim 40 and the polynucleotide molecule of claim 41.

45. The host cell of claim 44, wherein the host cell is a CHO cell.

46. A method of producing an immunoglobulin protein, comprising growing the host cell of claim 44 under conditions permitting production of the protein, and recovering the protein so produced.

47. The method of claim 46, wherein the host cell is a CHO cell.

48. A pharmaceutical composition comprising the agent of claim 1 and a pharmaceutically acceptable carrier or diluent.

49. A pharmaceutical composition comprising a therapeutically effective amount of the agent of claim 1 for use in reversing the hemodynamic effects of a NPR1 agonist, wherein the pharmaceutical composition is to be administered to a subject in need thereof.

50. The pharmaceutical composition for use of claim 49, wherein the composition is to be administered subcutaneously, intravenously, intradermally, intraperitoneally, or intramuscularly to the subject.

51. The pharmaceutical composition for use of claim 49, wherein the subject has a disease or disorder selected from the group consisting of hypertension, heart failure, and chronic kidney disease.